Regeneron/REGN

$896.66

-0.21%
-
1D1W1MYTD1YMAX

About Regeneron

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others. The Company’s solid tumor and other oncology and autoimmune cell therapy programs include the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets.

Ticker

REGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Leonard Schleifer

Employees

13,450

Headquarters

Tarrytown, United States

Regeneron Metrics

BasicAdvanced
$99.3B
Market cap
26.03
P/E ratio
$34.76
EPS
0.16
Beta
-
Dividend rate
$99.3B
0.15727
$998.33
$684.81
467.36K
5.69
4.936
10.407
10.407
26.437
12.69%
16.26%
14.19%
26.026
7.57
3.811
3.983
27.075
7.76%
-9.09%
15.57%
4.44%

What the Analysts think about Regeneron

Analyst Ratings

Majority rating from 28 analysts.
Buy

Price Targets

Average projection from 23 analysts.
16.91% upside
High $1,189.00
Low $720.00
$896.66
Current price
$1,048.33
Average price target

Regeneron Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
33.76% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$3.43B
2.13%
Net income
$1.16B
15.06%
Profit margin
33.76%
12.68%

Regeneron Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 10.53%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$10.09
$10.24
$11.59
$11.86
-
Expected
$9.56
$9.84
$10.72
$10.73
$10.10
Surprise
5.57%
4.03%
8.13%
10.53%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Regeneron stock?

Regeneron (REGN) has a market cap of $99.3B as of April 16, 2024.

What is the P/E ratio for Regeneron stock?

The price to earnings (P/E) ratio for Regeneron (REGN) stock is 26.03 as of April 16, 2024.

Does Regeneron stock pay dividends?

No, Regeneron (REGN) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next Regeneron dividend payment date?

Regeneron (REGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Regeneron?

Regeneron (REGN) has a beta rating of 0.16. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Regeneron stock price target?

The target price for Regeneron (REGN) stock is $1048.33, which is 16.91% above the current price of $896.66. This is an average based on projections from 23 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Regeneron stock

Buy or sell Regeneron stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing